HERS Protocol 3 — Hepatic Encephalopathy Recovery & Support
Managing HE with Hepatocellular CarcinomaLiver Cancer — Adapted Protocol for Patients and Caregivers
← Back to main protocol
This protocol is adapted for HE occurring in the context of hepatocellular carcinoma (HCC). The core HE management interventions remain relevant, but the goals, constraints, and context are meaningfully different. This is primarily a supportive care and quality-of-life document. It does not address HCC treatment itself. Check all supplements against current cancer treatment medications — drug interactions matter in this context.
⚡ What's Different with HCC
HE arising in liver cancer is fundamentally different in its trajectory and goals from HE arising in cirrhosis alone:
- Recovery trajectory is uncertain. In alcohol-related or NASH cirrhosis, the goal is liver stabilization and HE prevention over months to years. In HCC, the liver's functional reserve is being actively reduced by tumor burden and often by treatment itself.
- Drug interactions are a primary concern. Sorafenib, lenvatinib, immunotherapy (nivolumab, pembrolizumab), and transarterial chemoembolization (TACE) all have metabolic and hepatic implications that affect supplement safety.
- Appetite and intake are often severely reduced — nutritional support strategies need to meet the patient where they are, not where guidelines suggest they should be.
- Sarcopenia is often advanced — muscle loss accelerates dramatically in cancer cachexia, making protein and BCAA support even more important and more urgent.
- Pain management creates complexity — opioids and other analgesics are hepatically processed and can worsen HE; this cannot simply be avoided.
- Goals of care may be palliative — in advanced HCC, managing HE may be about maintaining quality of life and cognitive presence rather than long-term recovery.
Understanding HE in HCC
Hepatocellular carcinoma arises in a cirrhotic liver in roughly 80–90% of cases — meaning most HCC patients already have the underlying liver damage that creates HE risk. As tumor burden increases and functional liver tissue is displaced or destroyed, the liver's ammonia-clearing capacity diminishes further. HE in HCC patients therefore tends to be a later-stage complication, often indicating significant disease progression.
This context doesn't make management less important — it makes it more so. Cognitive clarity profoundly affects quality of life and the ability to participate in treatment decisions. Managing ammonia load, maintaining nutritional status, and preventing precipitating events remains meaningful even when curative intent has shifted to palliative support.
What this protocol offers is the most practical set of safe, low-cost interventions for ammonia management in this specific population — with honest notes on what to check against your current treatment regimen.
⚠ Check Everything Against Current Treatment
Before beginning any supplement in this protocol, review with the oncology or hepatology team — or at minimum a pharmacist. Key interaction concerns:
- Sorafenib / Lenvatinib: These are CYP3A4 substrates; berberine (not in this protocol for HCC) and some probiotics may modestly affect levels. LOLA, MiraLax, zinc, and magnesium have no established interactions.
- Immunotherapy (checkpoint inhibitors): Probiotic use during immunotherapy is an evolving area — some evidence suggests gut microbiome composition affects immunotherapy response. Discuss with the oncology team before starting probiotics.
- Vitamin E: May have anticoagulant effects at high doses — relevant if on anticoagulation for portal vein thrombosis, which is common in HCC. Not included in this protocol for that reason.
- ALCAR: No established interactions with standard HCC regimens, but always verify.
The Adapted Stack
Bowel Management
MiraLax (Polyethylene Glycol 3350)
1 capful daily — titrate to 2–3 soft, formed stools per day
Bowel management remains the most direct and safest intervention for ammonia control in HCC-related HE. MiraLax has no drug interactions and is safe regardless of current cancer treatment. Consistent bowel clearance reduces transit time for ammonia-producing gut bacteria. If appetite is very reduced and intake is low, bowel frequency may naturally be lower — titrate to what the actual intake supports, with 1–2 formed stools per day as a reasonable minimum.
Core Ammonia Reduction
LOLA (L-Ornithine L-Aspartate)
6–18g/day as tolerated. In patients with significantly reduced appetite, 6–9g/day is a realistic starting point.
LOLA supports the residual urea cycle capacity in the remaining functional liver tissue. No established drug interactions with standard HCC therapies. In advanced disease with severely reduced functional liver mass, the benefit may be more modest — but ammonia clearance support via any residual urea cycle activity is worthwhile. Nausea can overlap with treatment-related nausea; taking with food or in smaller divided doses helps.
Sourcing: BulkSupplements.com — pharmaceutical-grade LOLA powder, COA available, 1kg quantity. Digital milligram scale essential for powder dosing.
Gut Microbiome Support
Sunfiber (Partially Hydrolyzed Guar Gum)
Per label, once daily — tasteless, mixes into any drink
Prebiotic fiber supports microbiome balance with no drug interactions. In patients with reduced appetite, it can be added to a small amount of yogurt or a protein drink without affecting palatability.
Gut Microbiome — discuss with oncology team first
Visbiome or Lactobacillus-dominant probiotic
10–50 billion CFU once daily — after confirming with oncology team
Probiotics have HE-specific benefit and are generally well-tolerated. However, emerging evidence suggests gut microbiome composition meaningfully affects immunotherapy response — if the patient is receiving checkpoint inhibitor therapy, discuss probiotic use with the oncologist before starting. Outside of immunotherapy, probiotics are a safe and beneficial addition.
Muscle Preservation — High Priority in HCC
BCAAs (Branched-Chain Amino Acids)
12–20g/day — in divided doses throughout the day if full serving is difficult to tolerate at once
Cancer cachexia and cirrhosis-related sarcopenia together create an accelerated muscle wasting environment in HCC. BCAAs are metabolized in muscle rather than liver, providing a safe anabolic signal without hepatic burden. BCAA supplementation in HCC-cirrhosis patients has specific evidence for improving event-free survival and tolerability of cancer treatment. EASL and AASLD guidelines both recommend BCAA supplementation in cirrhotic patients with HCC.
When oral intake is severely limited, BCAAs can be mixed into small amounts of fluid and taken incrementally — they don't need to be consumed all at once.
When oral intake is severely limited, BCAAs can be mixed into small amounts of fluid and taken incrementally — they don't need to be consumed all at once.
Protein — Meet the Patient Where They Are
Casein or Whey Protein + frequent small protein servings
Target 1.2–1.5g/kg/day. If full intake is not achievable, prioritize BCAAs and any protein that can be tolerated — eggs, yogurt, protein drinks in small volumes.
Cancer cachexia makes protein intake genuinely difficult. The goal is not a rigid target but a consistent effort to prevent fasting-induced muscle catabolism. Even small, frequent protein sources throughout the day reduce the ammonia burden from muscle breakdown. Casein at night remains the best-tolerated evening protein for ammonia management.
Neuroprotective Support
Acetyl-L-Carnitine (ALCAR)
1–2g twice daily as tolerated
Carnitine deficiency is pronounced in cancer cachexia and liver disease combined. ALCAR supports mitochondrial function, crosses the blood-brain barrier, and has shown cognitive benefit in HE patients. In cancer patients, ALCAR has also shown benefit for chemotherapy-induced peripheral neuropathy and fatigue — overlapping benefits in this population. No established interactions with sorafenib or lenvatinib.
Urea Cycle Cofactor
Zinc (gluconate or bisglycinate)
25mg daily
Zinc deficiency is universal in cirrhosis and common in cancer patients. Direct urea cycle cofactor. No interactions with standard HCC therapies at this dose.
Pain Management and HE — A Difficult Balance
Pain is a reality for many HCC patients, and the safest analgesics for liver disease are a limited set. This is worth knowing so caregivers can advocate intelligently:
Acetaminophen (Tylenol): Counterintuitively, acetaminophen in low doses (maximum 2g/day, ideally less) is safer for liver disease patients than NSAIDs. NSAIDs worsen kidney function and precipitate hepatorenal syndrome in cirrhosis. Acetaminophen at low doses is acceptable — the key is not exceeding 2g/day and avoiding it with alcohol.
NSAIDs (ibuprofen, naproxen): Avoid. Worsen renal function and can precipitate HE through dehydration and electrolyte disruption.
Opioids: Often necessary in advanced HCC. All opioids are sedating and most are hepatically processed — they will worsen HE at higher doses. This is a goals-of-care conversation, not a supplement conversation. Ensure the care team knows that HE is present so they can calibrate opioid dosing accordingly. Oxycodone and hydromorphone are sometimes better tolerated in hepatic impairment than morphine (which has an active metabolite that accumulates).
Gabapentin/Pregabalin: Sometimes used for pain. Renally cleared, not hepatically processed — generally safer in this context, but sedating effects still compound HE.
NSAIDs (ibuprofen, naproxen): Avoid. Worsen renal function and can precipitate HE through dehydration and electrolyte disruption.
Opioids: Often necessary in advanced HCC. All opioids are sedating and most are hepatically processed — they will worsen HE at higher doses. This is a goals-of-care conversation, not a supplement conversation. Ensure the care team knows that HE is present so they can calibrate opioid dosing accordingly. Oxycodone and hydromorphone are sometimes better tolerated in hepatic impairment than morphine (which has an active metabolite that accumulates).
Gabapentin/Pregabalin: Sometimes used for pain. Renally cleared, not hepatically processed — generally safer in this context, but sedating effects still compound HE.
Daily Timing — Adapted for Reduced Appetite
Morning — with whatever breakfast is tolerated
B-50 Complex · Vitamin D3 + K2 · MiraLax · LOLA (starting dose) · Sunfiber · Zinc 25mg · Probiotic (if cleared with oncology)
Midday — small protein serving
LOLA second dose · BCAAs (partial serving if full serving not tolerated) · Any protein: yogurt, egg, protein drink · Do not allow 4 hours without food if at all possible
Evening
LOLA evening dose · BCAAs (remaining serving) · ALCAR · Casein protein if tolerated · Magnesium Glycinate 400mg (supports sleep, urea cycle, muscle function)
Throughout the Day
Water consistently · Electrolytes as tolerated (Pedialyte or homemade) · Avoid sedating antihistamines and sleep aids where possible
Diet — Practical Guidance for Reduced Appetite
- Any protein is better than no protein. When appetite is severely reduced, rigid dietary rules are less important than getting adequate nutrition in whatever form is tolerated.
- Small, frequent offerings every 2–3 hours — large meals are often not tolerable and aren't necessary.
- High-density, easy-to-eat protein sources: eggs, Greek yogurt, protein shakes, nut butters, cottage cheese.
- Limit ammonia burden: avoid large amounts of red meat when possible; prefer fish, eggs, dairy.
- No added sugar where possible — even in this context, excess sugar adds hepatic workload.
- Caloric density matters — full-fat yogurt, avocado, olive oil are energy-dense and liver-friendly.
- If oral intake is severely compromised, discuss nutritional supplementation options (fortified medical nutrition drinks) with the care team.
Monitoring
In HCC with HE, cognitive changes can reflect multiple processes simultaneously — disease progression, medication effects, and ammonia accumulation. The monitoring approach remains pattern recognition, but the context requires more nuance.
Asterixis check: Arms extended, palms up, eyes closed, hold 15–20 seconds. Rhythmic flapping is HE-specific. In cancer patients also receiving opioids or other medications, distinguishing asterixis from medication effect can be difficult — any new or worsening flapping warrants a call to the care team.
Daily orientation check: Same questions each day. Compare to yesterday. In HCC, cognitive decline may reflect disease progression as well as HE — the monitoring helps separate a sudden change (potentially treatable precipitant) from a gradual trend (disease trajectory).
Bowel log: Target 1–2 formed stools per day in this population (intake is lower, so 3x/day is often unrealistic). Less than 1/day warrants an additional MiraLax dose.
Daily orientation check: Same questions each day. Compare to yesterday. In HCC, cognitive decline may reflect disease progression as well as HE — the monitoring helps separate a sudden change (potentially treatable precipitant) from a gradual trend (disease trajectory).
Bowel log: Target 1–2 formed stools per day in this population (intake is lower, so 3x/day is often unrealistic). Less than 1/day warrants an additional MiraLax dose.
Signs to Seek Care
- Asterixis new or clearly worsening — especially any change distinguishable from baseline medication sedation
- Clear step-backward in orientation over 24–48 hours
- Fever — infection in immunocompromised cancer patients requires prompt evaluation
- GI bleeding — dark/tarry stools or vomiting blood; portal hypertension in HCC makes variceal bleeding a real risk
- Jaundice rapidly deepening — indicates significant hepatic decompensation
- Severe new abdominal pain — may indicate tumor rupture or other emergency
- Inability to keep any fluids down
- Any loss of consciousness
HE in the context of liver cancer is one of the most difficult versions of an already difficult situation. Managing it well doesn't change the underlying disease — but it can preserve the cognitive clarity that allows a person to remain present, make decisions, and spend meaningful time with the people who matter. That is not a small thing. It is, in many situations, everything.
Key References
Goh ET et al. LOLA for HE in cirrhosis. Cochrane Database, 2018.
EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019.
Amodio P et al. Nutritional management of HE: ISHEN guidelines. Hepatology, 2013.
Rahimi RS et al. Lactulose vs PEG 3350 for Overt HE. JAMA Internal Medicine, 2014.
Muto Y et al. BCAA supplementation in liver cirrhosis with HCC. Journal of Hepatology, 2005.
Malaguarnera M et al. ALCAR in HE. Hepatology, 2011.